Canaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)

Diaceutics (LON:DXRX - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Canaccord Genuity Group in a report issued on Tuesday, MarketBeat reports. They currently have a GBX 160 ($2.03) price target on the stock. Canaccord Genuity Group's price target indicates a potential upside of 31.15% from the company's previous close.

Diaceutics Price Performance

LON DXRX traded up GBX 2.50 ($0.03) during trading on Tuesday, reaching GBX 122 ($1.55). 32,192 shares of the company traded hands, compared to its average volume of 108,394. Diaceutics has a 1-year low of GBX 84.50 ($1.07) and a 1-year high of GBX 136 ($1.73). The company has a market cap of £103.05 million, a price-to-earnings ratio of -4,081.67 and a beta of 0.58. The stock's 50 day moving average price is GBX 122.48 and its two-hundred day moving average price is GBX 126.35. The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85.

Diaceutics Company Profile

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.